ES2981617T3 - Combinación para el tratamiento de infecciones provocadas por Mycoplasma genitalium - Google Patents
Combinación para el tratamiento de infecciones provocadas por Mycoplasma genitalium Download PDFInfo
- Publication number
- ES2981617T3 ES2981617T3 ES20739585T ES20739585T ES2981617T3 ES 2981617 T3 ES2981617 T3 ES 2981617T3 ES 20739585 T ES20739585 T ES 20739585T ES 20739585 T ES20739585 T ES 20739585T ES 2981617 T3 ES2981617 T3 ES 2981617T3
- Authority
- ES
- Spain
- Prior art keywords
- gepotidacin
- doxycycline
- pharmaceutically acceptable
- acceptable salt
- mycoplasma genitalium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870990P | 2019-07-05 | 2019-07-05 | |
| US202062985465P | 2020-03-05 | 2020-03-05 | |
| PCT/EP2020/068754 WO2021004910A1 (en) | 2019-07-05 | 2020-07-03 | Combination for the treatment of infections caused by mycoplasma genitalium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2981617T3 true ES2981617T3 (es) | 2024-10-09 |
Family
ID=71579551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20739585T Active ES2981617T3 (es) | 2019-07-05 | 2020-07-03 | Combinación para el tratamiento de infecciones provocadas por Mycoplasma genitalium |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220257615A1 (https=) |
| EP (1) | EP3993796B1 (https=) |
| JP (1) | JP7638263B2 (https=) |
| CN (1) | CN114173789A (https=) |
| BR (1) | BR112021024845A2 (https=) |
| CA (1) | CA3143619A1 (https=) |
| ES (1) | ES2981617T3 (https=) |
| WO (1) | WO2021004910A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11917094B2 (en) * | 2021-02-01 | 2024-02-27 | Aptiv Technologies Limited | Automatic control of smartphone driver mode using ultra-wideband communication |
| EP4288035A1 (en) * | 2021-02-05 | 2023-12-13 | GlaxoSmithKline Intellectual Property Development Limited | Oral solid dose formulations |
| JP2025532252A (ja) | 2022-09-26 | 2025-09-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 処置方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| US9993469B2 (en) | 2013-05-28 | 2018-06-12 | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections |
| US10702521B2 (en) * | 2014-08-22 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones |
| WO2018195098A1 (en) * | 2017-04-17 | 2018-10-25 | Ohio State Innovation Foundation | Type ii topoisomerase inhibitors and methods of making and using thereof |
-
2020
- 2020-07-03 US US17/619,367 patent/US20220257615A1/en not_active Abandoned
- 2020-07-03 EP EP20739585.6A patent/EP3993796B1/en active Active
- 2020-07-03 JP JP2022500047A patent/JP7638263B2/ja active Active
- 2020-07-03 ES ES20739585T patent/ES2981617T3/es active Active
- 2020-07-03 WO PCT/EP2020/068754 patent/WO2021004910A1/en not_active Ceased
- 2020-07-03 BR BR112021024845A patent/BR112021024845A2/pt unknown
- 2020-07-03 CN CN202080049062.5A patent/CN114173789A/zh active Pending
- 2020-07-03 CA CA3143619A patent/CA3143619A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021024845A2 (pt) | 2022-01-18 |
| JP2022539583A (ja) | 2022-09-12 |
| JP7638263B2 (ja) | 2025-03-03 |
| EP3993796C0 (en) | 2024-02-21 |
| CA3143619A1 (en) | 2021-01-14 |
| WO2021004910A1 (en) | 2021-01-14 |
| US20220257615A1 (en) | 2022-08-18 |
| EP3993796A1 (en) | 2022-05-11 |
| EP3993796B1 (en) | 2024-02-21 |
| CN114173789A (zh) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yaghoubi et al. | Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review | |
| ES2981617T3 (es) | Combinación para el tratamiento de infecciones provocadas por Mycoplasma genitalium | |
| Silver et al. | Discovery and development of new antibiotics: the problem of antibiotic resistance | |
| JP2025084772A (ja) | 細菌性尿路感染症の治療に使用するためのゲポチダシン | |
| WO2013119564A1 (en) | Antibacterial agents: combination of a rifamycin and a switch region inhibitor | |
| BRPI0916885B1 (pt) | composição farmacêutica | |
| Yamaguchi et al. | Antimicrobial susceptibility of Enterococcus strains used in clinical practice as probiotics | |
| Tomioka et al. | Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex | |
| EP1223935A1 (en) | Methods of use of fluoroquinolone compounds against bacteria | |
| ES3004932T3 (en) | Regimen for treating a neisseria gonorrhoeae infection with gepotidacin | |
| US7595328B2 (en) | Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria | |
| US20250099535A1 (en) | Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus | |
| ES2982067T3 (es) | Métodos, usos y composiciones del tratamiento con rifabutina | |
| US20240108620A1 (en) | Treatment Regimen | |
| Blondeau et al. | Role of gemifloxacin in the management of community-acquired lower respiratory tract infections | |
| US20220184071A1 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| CN1852738A (zh) | 使用伊马替尼和米哚妥林治疗胃肠道基质肿瘤 | |
| KIZILAY | PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF MOXIFLOXACIN | |
| EP2968283A1 (en) | Rifaximin for use in the treating of vaginal infections. | |
| CN110141569A (zh) | 抗牛多杀性巴氏杆菌的药物组合物 | |
| Iannini | Treatment of Community-Acquired Respiratory Tract Infections with Ketolides |